GB2548873A — Use of cannabinoids in treatment of epilepsy
Assigned to GW Research Ltd · Expires 2017-10-04 · 9y expired
What this patent protects
The use of the cannabinoid cannabidiol (CBD) in the treatment of Sturge Weber syndrome. The invention is particularly directed to reducing either seizure ornon-seizure symptoms in patients suffering with Sturge Weber syndrome. Cannabidiol may be used in combination with one or mo…
USPTO Abstract
The use of the cannabinoid cannabidiol (CBD) in the treatment of Sturge Weber syndrome. The invention is particularly directed to reducing either seizure ornon-seizure symptoms in patients suffering with Sturge Weber syndrome. Cannabidiol may be used in combination with one or more concomitant anti-epileptic drugs for the treatment of Sturge Weber syndrome. In some instances the CBD used is in the form of a highly purified extract of cannabis such that the CBD is present at greater than 98% of the total extract (w/w). In some cases the cannabinoid tetrahydrocannabinol (THC) has been substantially removed, to a level of not more than 0.15% (w/w) and the propyl analogue of CBD, cannabidivarin, (CBDV) is present in amounts of up to 1%. Alternatively, the CBD may be a synthetically produced CBD.
Drugs covered by this patent
- Epidiolex (CANNABIDIOL) · Jazz Pharms Res
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.